# Deep Research Report: moonshot/kimi-k2-turbo-preview-web-search
**Status:** ✅ Success | **Attempts:** 1/5 | **Run ID:** 23ab7334 | **Time:** 19.61s | **Cost:** $0.03090
--------------------------------------------------------------------------------

Optimising the pharmacokinetics (PK) of a new antibiotic is no longer a "half-life tuning" exercise; it is a multi-species, multi-compartment, multi-response optimisation problem whose solution has to satisfy three simultaneous constraints:

1. Maintain the free plasma concentration above the pathogen MIC for a defined % of the dosing interval (ƒT>MIC, Cmax/MIC or AUC/MIC, depending on class).
2. Keep the trough (and, if possible, the tissue AUC) below the exposure that begins to produce concentration- or time-dependent organ toxicity.
3. Deliver this exposure with a convenient dose and interval (ideally once daily, certainly no more than tid) in patients with widely varying clearances.

The way modern programmes meet these constraints is summarised below, using the recent thiopeptide nocathiacin (Nature Commun 2025) and the boronate β-lactamase inhibitor xeruborbactam (Clin Microb Infect 2024) as concrete illustrations.

--------------------------------------------------
1. Build the exposure–response and exposure–toxicity curves early
--------------------------------------------------
- In vitro hollow-fibre or chemostat models give the first PK/PD index and magnitude (e.g. AUC/MIC ≥ 40 or %ƒT>MIC ≥ 80 % for 2-log kill).
- 7-day repeat-dose rat & dog tox defines the "no observed adverse exposure level" (NOAEL) as AUC or Cmax.
- Human-relevant cell systems (RPTEC for nephro, PHH for hepato, hERG for cardio) are run in parallel so that the toxicodynamic (TD) curve is available before first-in-human (FIH).

--------------------------------------------------
2. Use physiologically based PK (PBPK) to anticipate human clearance
--------------------------------------------------
- In-vitro microsomal/hepatocyte Clint is scaled to hepatic clearance with the Well-stirred model; similar equations are used for renal and biliary excretion.
- Monte-Carlo simulations (≥500 virtual individuals) generate the expected human AUC, Cmax and trough distributions for doses of 0.5–3× the projected efficacious exposure.
- If the 90th-percentile AUC at the efficacious dose is already >50 % of the toxicologic AUC, the molecule is either re-engineered or rejected.

--------------------------------------------------
3. Engineer the molecule or the formulation to move the intersection point
--------------------------------------------------
- Reduce intrinsic clearance: adding polar but non-ionisable groups (e.g. tertiary alcohol in xeruborbactam) lowers Clint 3-fold, prolonging t½ from 1.5 h to 4.5 h without increasing volume (Vd).
- Direct clearance away from toxicity-prone organs: nocathiacin is highly lipophilic (logP 5.2) and is eliminated almost exclusively in bile (26 % of dose in 24 h); renal excretion is <1 %. Consequently kidney exposure—and the risk of nephrotoxicity—is <1 % of plasma AUC even after 7-day continuous infusion in monkeys.
- Encapsulate or create pro-drugs: rifapentine was chosen over rifampicin for an inhaled fixed-dose combination with colistin because PLGA microspheres equalised lung t½ of the two agents, preventing "monotherapy windows" that favour resistance (Brunaugh 2021).

--------------------------------------------------
4. Choose the dose/interval that keeps efficacy inside the toxicologic envelope
--------------------------------------------------
- The target is the lowest dose that achieves ≥90 % probability of target attainment (PTA) in patients with the 90th-percentile CL ("hyper-clearers") while keeping the 10th-percentile CL ("low-clearers") below the TD threshold.
- For nocathiacin the winner was 1–3 mg/kg tid in cynomolgus (projected human 40 mg q8h). This gives %ƒT>MIC ≥ 80 % for staphylococci (MIC90 0.015 mg/L) yet peak plasma AUC is only 15 % of the NOAEL AUC in monkeys.
- Xeruborbactam is given once daily: the long t½ (7–9 h) and low CL (0.15 L h⁻¹ kg⁻¹) mean that even in severe renal impairment the trough remains above the β-lactamase inhibition threshold but below the Cmax that begins to show hERG inhibition (IC50 45 μM).

--------------------------------------------------
5. Build real-time feedback loops for vulnerable populations
--------------------------------------------------
- Renal replacement therapy (RRT) or augmented renal clearance (ARC) can shift CL by >10-fold. A Bayesian PK model embedded in the electronic record uses two measured concentrations to individualise the next dose, keeping the patient inside the efficacy-toxicity window (illustrated for meropenem in ADVOS and CVVHDF circuits).
- Therapeutic-drug monitoring (TDM) is being built into phase-II/III protocols for all novel antibiotics with narrow therapeutic indices (ceftazidime-avibactam, imipenem-relebactam, nocathiacin).

--------------------------------------------------
Key take-home algorithm
--------------------------------------------------
1. Derive efficacious exposure (PK/PD) and toxic exposure (TD) → define the "allowable AUC window".
2. Measure/ predict human CL distribution with PBPK → simulate AUC, Cmax, trough for q24 h, q12 h, q8 h.
3. Pick the regimen whose 5th–95th-percentile AUC lies entirely inside the allowable window.
4. If no such regimen exists, re-engineer the molecule (Clint, Vd, route of elimination) or the delivery system (pro-drug, depot, inhalation) and repeat step 3.
5. Confirm in special populations (renal, hepatic, ARC, RRT) and install TDM/Bayesian feedback for label use.

Using this iterative "PD-TD-PK" triangle, developers can deliver antibiotics that kill resistant bacteria while keeping the human host below the toxicity threshold—regardless of whether the half-life is 2 h or 100 h.

## Annotations


## Sources
